TVTX — Travere Therapeutics Share News
0.000.00%
Last trade - 00:00- $4.98bn
- $5.09bn
- $490.73m
Brief: Travere Therapeutics - Receives USPTO Notice Of Allowance For Filspari Patent In FSGS
Brief: Travere Therapeutics Announces Planned Chief Executive Officer Transition
Brief: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule
Travere Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Travere Therapeutics Q2 product sales rise on FILSPARI demand
Brief: Travere Therapeutics Q2 EPS USD -0.37
US FDA approves Vera's kidney disease drug (updated)
US FDA approves Vera's kidney disease drug
Brief: Travere Therapeutics Announces Planned Retirement Of Chief Research Officer In 2027
Travere licenses Everest's kidney disease drug in deal worth up to $1.14 billion
Brief: Travere Therapeutics Enters Into Exclusive Licensing Agreement With Everest Medicines For Civorebrutinib A Potential Best-In-Class Btk Inhibitor For Rare Kidney Diseases
Brief: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
U.S. STOCKS ON THE MOVE-Krispy Kreme, Tesla, Axon Enterprise
U.S. STOCKS ON THE MOVE-Albemarle, Howmet, Travere Therapeutics
Travere Therapeutics climbs after upsized $475 mln convertible financing
Brief: Travere Prices Upsized $475.0 Million Convertible Senior Notes Offering To Refinance 2029 Convertible Notes
Travere Therapeutics Q1 product sales rise on FILSPARI demand
Brief: Travere Therapeutics Q1 EPS USD -0.4